Royal Biologics announces the launch of MAGNUS, a DMSO-free viable cellular bone allograft
JANUARY 08, 2020
Royal Biologics, an ortho-biologics company specializing in the research and advancement of regenerative cellular therapy and novel orthobiologic solutions, has announced the launch of MAGNUS, a DMSO-free viable cellular bone allograft. MAGNUS presents a unique solution to traditional viable cellular allograft technology as it utilizes a DMSO-free cryoprotectant. This novel approach to the viable cellular allograft market differentiates MAGNUS from all other technologies currently available.
Proper preservation of cellular allografts requires strict adherence to recovery and processing protocols. In the MAGNUS viable cellular bone allograft, viable spine-derived cells are collected from the vertebral body region of the donor and preserved with the use of a DMSO-free cryoprotectant.
“We are very excited to add MAGNUS to our portfolio of novel orthobiologic solutions for fusion in orthopedics, says Salvatore Leo, Chief Executive Officer of Royal Biologics. MAGNUS presents a new class of viable cellular allografts which we feel present the surgeon with favorable options for bone graft based procedures.”
In a recently published peer-reviewed study looking at 75 consecutive cases with 12 months of follow up, MIS TLIF Fusion with MAGNUS Viable Allograft demonstrated a 96% fusion rate of the 75 patients with a total of 85 levels achieving fusion at 12 months.1
“MAGNUS presents a novel product class opportunity in orthopedics. We feel that the industry was calling for a DMSO-free viable graft solution and MAGNUS meets that demand.”
For more information on MAGNUS, MAXX-CELL, and Royal Biologics please visit www.royalbiologics.com
1Tally, William C, et al., Transforaminal Lumbar Interbody Fusion with Viable Allograft: 75 Consecutive Cases at 12-Month Follow-Up. International Journal of Spine Surgery, 2018. Vol. 12, No. 1 pp 76-84.
